Amplifying Outcomes: Checkpoint Inhibitor Combinations in First‐Line Non‐Small Cell Lung Cancer

PURPOSE: Lung cancer is one of the most common types of cancer, resulting in approximately 1.8 million deaths worldwide. Immunotherapy using checkpoint inhibitors has become standard of care in advanced non‐small cell lung cancer (NSCLC), and there is increasing interest in further improving outcome...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Melosky, Barbara, Juergens, Rosalyn, Hirsh, Vera, McLeod, Deanna, Leighl, Natasha, Tsao, Ming‐Sound, Card, Paul B., Chu, Quincy
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2019
Assuntos:
Lung Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6964132/
https://ncbi.nlm.nih.gov/pubmed/31138727
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0027
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados